UnknownNot Applicable

Diaplacental Transfer of Anti-HCMV- and Anti-VZV-immunoglobulin G (IgG) -Antibodies at Premature and Mature Newborns

Germany450 participantsStarted 2013-07

Plain-language summary

The aim of the study is to determine the total concentration of HCMV- and VZV-specific IgG-antibodies and the total concentration of neutralizing antibodies against HCMV in neonatal bloodstream depending on gestational age at birth.

Who can participate

Age range1 Minute – 10 Minutes

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * HCMV and/or VZV-seropositive pregnant woman who signed written informed consent form. Exclusion Criteria: * Newborns of underage mothers. * Newborns whose mother did not sign the written informed consent. * Pregnant women with a known hereditary or acquired immune deficiency

What they're measuring

To measure the concentration of specific HCMV-/VZV-IgG-antibodies in fetal bloodstream depending on gestational age at birth.

Timeframe: Newborn: immediately after birth; Mother +/- 3 days at birth

Trial details

NCT IDNCT02689700

SponsorJohann Wolfgang Goethe University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-12

Contact for this trial

Horst Buxmann, PI

+49 69 6301 horst.buxmann@kgu.de

View on ClinicalTrials.gov More Materno-fetal Transfer of Anti-HCMV-IgG trials